Skip to content
OpenCapital
Get started

TriSalus Life Sciences, Inc. TLSI Cash & Equivalents

Cash & Equivalents at other companies

Boston Scientific logo
Boston ScientificBSX
$850M+146%
AngioDynamics logo
AngioDynamicsANGO
$37.81M-15.5%
Delcath Systems logo
Delcath SystemsDCTH
$41.3M+223%
Tactile Systems Technology logo
Tactile Systems TechnologyTCMD
$74.99M-10.3%
LQD
Liquidia CorporationLQDA
$222.79M+31.2%
United Therapeutics logo
United TherapeuticsUTHR
$1.28B-32.6%

Other financials

Income statement

See full
Revenue$8.9M-2.9%
Gross profit$7.7M0.0%
Operating income-$8.4M-14.8%
Net income$1.5M+115%
EPS (diluted)$0.03+108%

Balance sheet

See full
Total debt$33.1M+4.4%
Total equity$12.8M+137%
Total assets$71.0M+148%

Cash flow

See full
Operating cash flow-$6.5M-44.0%
CapEx$141.0K-81.3%
Free cash flow-$6.6M-26.0%

Valuation

See full
Market cap$279.45M+49.6%
Enterprise value$255.97M+33.6%
P/S6.2×+1.0×

Profitability

See full
Gross margin85.1%-0.5pp
Operating margin-62.4%-16.8pp
Net margin-60.9%-13.4pp
FCF margin-45.2%-16.8pp

Returns & leverage

See full
Return on equity253.3%—
Debt / equity2.6×—
Current ratio5.8×+3.6×

Where this comes from

Reported directly by TriSalus Life Sciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: TriSalus Life Sciences, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about TriSalus Life Sciences, Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TriSalus Life Sciences, Inc.'s cash & equivalents?
TriSalus Life Sciences, Inc. (TLSI) reported cash & equivalents of $56.55M in Q1 2026.
How has TriSalus Life Sciences, Inc.'s cash & equivalents changed year-over-year?
TriSalus Life Sciences, Inc.'s cash & equivalents increased by 323.6% year-over-year, from $13.35M to $56.55M.
What is the long-term trend for TriSalus Life Sciences, Inc.'s cash & equivalents?
Over 5 years (2020 to 2025), TriSalus Life Sciences, Inc.'s cash & equivalents has grown at a 73.2% compound annual growth rate (CAGR), from $1.33M to $20.79M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.